When a Child Has Severe Type 1 SMA With Respiratory Failure: Fudan Pediatric MDT Team Finds the Answer

Spinal Muscular Atrophy (SMA) is a life-threatening neuromuscular rare disease caused by a defect in the SMN1 gene. Type 1 SMA is the most severe form. Infants typically show symptoms within the first six months of life, experiencing progressive muscle weakness and an inability to sit independently. The most fatal complications are respiratory failure due to respiratory muscle weakness, and malnutrition and recurrent aspiration pneumonia due to swallowing difficulties. Without treatment, most children do not survive beyond two years of age.

Standard approaches and their limitations:

• Traditional supportive care: Includes non-invasive ventilation, tube feeding, and rehabilitation. This can only "sustain life" but cannot halt disease progression. The child's quality of life remains very low, placing a heavy burden on the family.

• Disease-modifying therapies (DMTs): Drugs like Nusinersen (intrathecal injection) and Risdiplam (oral). However, for critically ill children already dependent on ventilators with severe respiratory failure, their efficacy may be limited, and the risks of administration are high.

• Gene replacement therapy (e.g., Zolgensma): Theoretically offers a one-time, long-term solution. Yet, for late-stage, critically ill children with low body weight and severe complications, its safety, efficacy, and accessibility (especially internationally) pose significant challenges.

The breakthrough solution:

This scenario demands a top-tier team with exceptional comprehensive rescue capabilities and a robust multidisciplinary team (MDT) system. Such a team must not only administer advanced therapies but also provide a full-cycle, integrated solution encompassing life support, precision treatment, and complex complication management for critically ill children.

Featured complex case: An international medical model. The Fudan Pediatric MDT Team successfully saves a critically ill Vietnamese child with Type 1 SMA.

• Hospital/Team: Fudan University Children's Hospital SMA Multidisciplinary Diagnosis and Treatment (MDT) Team (encompassing Neurology, Respiratory Medicine, Intensive Care, Rehabilitation, Clinical Nutrition, etc.).

• Patient profile: A child with Type 1 SMA from Vietnam, in an extremely critical condition upon arrival. The child was completely ventilator-dependent, with limb paralysis, severe malnutrition, and recurrent lung infections. This represented one of the most complex and challenging late-stage critical cases in SMA treatment, beyond the capacity of the local healthcare system.

• Core technology and integrated strategy: The Fudan team did not rely on a single therapy. Instead, they implemented an integrated medical protocol: "Life Support + Sequential Multi-Drug Therapy + Full-Cycle Precision Management." ICU care and life support: Stabilized the child's respiratory, circulatory, and nutritional status in the PICU, creating a safe window for subsequent treatment.

• Innovative combined drug therapy: Under close monitoring, the team formulated a bold yet precise individualized plan combining gene therapy and small-molecule drugs to maximize the rescue of motor neuron function.

• Full-cycle MDT management: Rehabilitation teams intervened early to prevent contractures, respiratory therapists managed weaning, and nutritionists optimized support. Every step involved collaborative decision-making by multidisciplinary experts.

• Outcome and significance: A medical miracle. After months of meticulous treatment, this child, once given a dire prognosis, successfully weaned off the ventilator, regained spontaneous breathing, and showed voluntary limb movement. They transitioned from a near-immobile state to a new life and were discharged home to Vietnam.

• International benchmark: This case stands as a model of China's rare disease diagnosis and treatment capabilities attracting international patients. It showcases China's comprehensive rescue strength and international leadership in ultra-complex, critical pediatric rare diseases.

• System value: It proves that for complex diseases like SMA, especially in critically ill children, a top-tier MDT system is more crucial than any single "miracle drug." Leveraging its platform as a National Children's Medical Center, Fudan Children's Hospital combines research (leading international multi-center trials), clinical practice (publishing China's SMA Clinical Practice Guidelines), and outreach (leading a national SMA Diagnosis and Treatment Center Alliance), creating a replicable and scalable "China Solution."

Faced with the global challenge of critical Type 1 SMA with respiratory failure, China's leading pediatric team provides the answer: powered by a national-level integrated MDT system, fusing intensive care, cutting-edge therapeutics, and precision rehabilitation to create the possibility of reversing fate. This case not only saved a life across borders but also demonstrated to the world that China has reached an internationally leading level in the diagnosis and treatment of complex, critical pediatric rare diseases.